|
SIGNIFICANT VENDOR (Detail) (USD $)
|
3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
Gene Expression And Protein Production [Member]
FhCMB [Member]
|
Sep. 30, 2011
Gene Expression And Protein Production [Member]
FhCMB [Member]
|
Jun. 30, 2011
Gene Expression And Protein Production [Member]
FhCMB [Member]
|
Sep. 30, 2012
LicKM [Member]
FhCMB [Member]
|
Sep. 30, 2011
LicKM [Member]
FhCMB [Member]
|
Jun. 30, 2011
LicKM [Member]
FhCMB [Member]
|
Sep. 30, 2012
FhCMB [Member]
|
Sep. 30, 2011
FhCMB [Member]
|
Dec. 31, 2012
FhCMB [Member]
|
|
| Research and Development Arrangement with Federal Government, Description and Terms | The most recent amendment to the TTA requires: 1) the Company to make payments to FhCMB of $2,000,000 per year for five years, aggregating $10,000,000, for such services beginning in November 2009; and 2) FhCMB to expend at least equal amounts during the same timeframe for research and development services related to the commercialization of the Technology | ||||||||||
| Related Party Transaction Minimum Annual Payment | $ 200,000 | ||||||||||
| Related Party Transaction, Expenses from Transactions with Related Party | 0 | 264,000 | 0 | 211,000 | 550,000 | 626,000 | |||||
| Interest Expense | 15,407 | 9,576 | 15,000 | 10,000 | |||||||
| Related Party Transaction, Amounts of Transaction | $ 1,660,000 | $ 432,000 | |||||||||